REPLIGEN CORPORATION (RGEN)

symbol lookup

Follow RGEN via My Validea and receive an email alert whenever any of our strategies changes its rating.

Get Started
Score: 79/100
Analysis based upon 8/20/2019 closing price.
Latest Close: $92.15 Market Cap ($ mil): $4,749 Sector: Healthcare Industry: Biotechnology & Drugs 52 Week High: $99.25 52 Week Low: $48.26 Relative Strength: 96 Twelve Minus One Return: 74.9%
PE Ratio: 163.1 Price/Sales: 20.4 Price/Book: 5.0 Price/Cash Flow: 109.0 EV/EBITDA: 75.71 Yield: N/A Shareholder Yield: -7.60% Value Composite Percentile: 90
Return on Equity: 3.6% Return on Tangible Capital: 18.8% Return on Invested Capital: 5.4% WACC: 7.7% Debt/Equity: 0.12 LT EPS Growth: 4.4% LT Sales Growth: 29.2% Quality Composite Percentile: 1
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company's portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.

Report Card - Small-Cap Growth Investor

Guru Criteria: Motley Fool  
PROFIT MARGIN:PASS
RELATIVE STRENGTH:PASS
COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR:PASS
INSIDER HOLDINGS:PASS
CASH FLOW FROM OPERATIONS:PASS
PROFIT MARGIN CONSISTENCY:FAIL
R&D AS A PERCENTAGE OF SALES:PASS
CASH AND CASH EQUIVALENTS:PASS
INVENTORY TO SALES:PASS
ACCOUNTS RECEIVABLE TO SALES:PASS
LONG TERM DEBT/EQUITY RATIO:PASS
"THE FOOL RATIO" (P/E TO GROWTH):FAIL
AVERAGE SHARES OUTSTANDING:PASS
SALES:PASS
DAILY DOLLAR VOLUME:FAIL
PRICE:PASS
INCOME TAX PERCENTAGE:FAIL

Detailed Analysis

Get a full analysis of RGEN using this and 11 other strategies of investment legends.

Start Your Free Trial